Table 2. Univariate and multivariate analysis for PFS in DLBCL cases.

Variables	Univariate analysis		multivariate analysis
	HR (95%CI)	P-value	HR (95%CI)	P-value
Sex (Male/Female)	0.65(0.36–1.16)	0.143	0.84(0.44–1.61)	0.591
Age (>60/≤60)	1.09(0.55–2.15)	0.813	1.18(0.55–2.58)	0.669
B symptom (Yes/No)	1.03(0.74–1.45)	0.853	0.80(0.35–1.81)	0.588
Stage (III/IV/I/II)	3.32(1.81–6.10)	<0.001	5.04(2.34–10.83)	<0.001
LDH (elevated/normal)	3.19(1.76–5.77)	<0.001	3.18(1.48–6.83)	0.003
β2-MG (elevated/normal)	1.61(0.88–2.94)	0.123	0.63(0.29–1.38)	0.249
HBsAg (+/−)	0.85(0.43–1.69)	0.649	0.47(0.22–1.01)	0.052
Immunophenotype (ABC/GCB)	1.22(0.60–2.47)	0.582	0.68(0.31–1.51)	0.344
Rituximab plus (Yes/No)	0.43(0.24–0.78)	0.005	0.40(0.20–0.79)	0.008
rs1799964 CC/TC+TT	1.07(0.53–2.17)	0.857	4.74(0.94–23.9)	0.059
rs1800683 AA/AG+GG	1.50(1.10–2.04)	0.01	2.04(1.01–4.14)	0.049
rs1800872 GG/TG+TT	0.68(0.41–1.13)	0.138	0.89(0.09–1.92)	0.076
rs2167270 AA/AG+GG	1.04(0.51–2.12)	0.904	0.84(0.18–3.84)	0.817
rs1327118 GG/GC+CC	4.58(0.07–9.14)	0.479	6.06(0.01–12.7)	0.967
rs1045241 TT/TC+CC	1.06(0.69–1.62)	0.806	1.85(0.70–4.88)	0.212